Quantitative lateral flow assay for meropenem determination: a proof-of-concept study
Author(s)
Type
Journal Article
Abstract
Therapeutic drug monitoring (TDM) is essential for optimizing antibiotic dosing, particularly in critically ill patients. However, conventional methods, such as LC/MS, have long turnaround times, limiting timely dose adjustment. We developed a novel competitive lateral flow assay (LFA) format with dual test lines previously validated for vancomycin and adapted it for Meropenem quantification. Using BlaR-CTD, a beta-lactam receptor protein, in place of an antibody and biotinylated BSA–Meropenem conjugated to gold nanoparticles, the LFA produced a concentration-dependent change in test line intensities. A custom image analysis algorithm showed strong correlation with Meropenem concentrations (R2 = 0.9537). The platform demonstrates the potential for rapid, point-of-care antibiotic monitoring across diverse healthcare settings. While further optimization is needed for low-concentration accuracy, this proof-of-concept supports broader applicability to other beta-lactams.
Date Issued
2025-10-14
Date Acceptance
2025-09-30
Citation
ACS Omega, 2025, 10 (40), pp.47566-47569
ISSN
2470-1343
Publisher
American Chemical Society
Start Page
47566
End Page
47569
Journal / Book Title
ACS Omega
Volume
10
Issue
40
Copyright Statement
© 2025 The Authors. Published by American Chemical Society. This publication is licensed under CC-BY 4.0 (https://creativecommons.org/licenses/by/4.0/)
License URL
Identifier
10.1021/acsomega.5c07602
Publication Status
Published
Date Publish Online
2025-10-06